Cancer

Title
The Study of Combined Study Medications in Patients With Positive Metastatic Melanoma
Trial Number
204714091912
Number of Participants
185
Principal Investigator

Joseph Clark

M.D.
Hematology/Oncology
Professor
Eligibility

Patients must be 18 years of age or older, and have the following: confirmed and measurable metastatic melanoma with the BRAFV600 mutation; at least one metastatic melanoma lesion accessible for biopsy prior to vemurafenib treatment if no archived tissue is available; meet the requirements for HD IL-2 therapy per institutional guidelines; meet the requirements for vemurafenib therapy per institutional guidelines.

Purpose

The purpose of this research study is to evaluate the response of your disease to vemurafenib and HD IL-2 when given in sequence (one after the other). Your disease response to the series of drugs is evaluated at about 10 and 26 weeks after the first dose of HD IL-2.

Enrollment

(708) 327-3221

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.